Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies

CM Perou, 2000, Molecular portraits of human breast tumours., Nature, 406, 747, 10.1038/35021093

T Sorlie, 2001, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications., Proc Natl Acad Sci U S A, 98, 10869, 10.1073/pnas.191367098

T Sorlie, 2003, Repeated observation of breast tumor subtypes in independent gene expression data sets., Proc Natl Acad Sci U S A, 100, 8418, 10.1073/pnas.0932692100

G Callagy, 2003, Molecular classification of breast carcinomas using tissue microarrays., Diagn Mol Pathol, 12, 27, 10.1097/00019606-200303000-00004

DS Oh, 2006, Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers., J Clin Oncol, 24, 1656, 10.1200/JCO.2005.03.2755

MC Cheang, 2009, Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer., J Natl Cancer Inst, 101, 736, 10.1093/jnci/djp082

TO Nielsen, 2004, Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma., Clin Cancer Res, 10, 5367, 10.1158/1078-0432.CCR-04-0220

LA Carey, 2006, Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study., JAMA, 295, 2492, 10.1001/jama.295.21.2492

EA Rakha, 2007, Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression., Histopathology, 50, 434, 10.1111/j.1365-2559.2007.02638.x

MC Cheang, 2008, Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype., Clin Cancer Res, 14, 1368, 10.1158/1078-0432.CCR-07-1658

M Jumppanen, 2007, Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers., Breast Cancer Res, 9, R16, 10.1186/bcr1649

M Tischkowitz, 2007, Use of immunohistochemical markers can refine prognosis in triple negative breast cancer., BMC Cancer, 7, 134, 10.1186/1471-2407-7-134

AM Mulligan, 2008, Prognostic effect of basal-like breast cancers is time dependent: evidence from tissue microarray studies on a lymph node-negative cohort., Clin Cancer Res, 14, 4168, 10.1158/1078-0432.CCR-07-4543

DA Berry, 2006, Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer., JAMA, 295, 1658, 10.1001/jama.295.14.1658

I Jatoi, 1995, Screening for breast cancer, time to think - and stop?, Lancet, 346, 436, 10.1016/S0140-6736(95)92808-1

EM Azzato, 2009, Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates?, Br J Cancer, 100, 1806, 10.1038/sj.bjc.6605062

2006, Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium., J Natl Cancer Inst, 98, 1382, 10.1093/jnci/djj374

GM Callagy, 2006, Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index., Clin Cancer Res, 12, 2468, 10.1158/1078-0432.CCR-05-2719

MK Schmidt, 2007, Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation., J Clin Oncol, 25, 64, 10.1200/JCO.2006.06.3024

K Syrjakoski, 2000, Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients., J Natl Cancer Inst, 92, 1529, 10.1093/jnci/92.18.1529

O Kilpivaara, 2005, Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients., Int J Cancer, 113, 575, 10.1002/ijc.20638

R Fagerholm, 2008, NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer., Nat Genet, 40, 844, 10.1038/ng.155

JE Olson, 2007, A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches., Breast Cancer Res Treat, 102, 237, 10.1007/s10549-006-9324-7

GG Giles, 2002, The Melbourne Collaborative Cohort Study., IARC Sci Publ, 156, 69

M Garcia-Closas, 2006, Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses., Hum Genet, 119, 376, 10.1007/s00439-006-0135-z

G MacPherson, 2004, Association of a common variant of the CASP8 gene with reduced risk of breast cancer., J Natl Cancer Inst, 96, 1866, 10.1093/jnci/dji001

S Rafii, 2002, A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer., Hum Mol Genet, 11, 1433, 10.1093/hmg/11.12.1433

J Ragaz, 1997, Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer., N Engl J Med, 337, 956, 10.1056/NEJM199710023371402

J Ragaz, 2005, Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial., J Natl Cancer Inst, 97, 116, 10.1093/jnci/djh297

J Stingl, 2007, Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis., Nat Rev Cancer, 7, 791, 10.1038/nrc2212

R Rouzier, 2005, Breast cancer molecular subtypes respond differently to preoperative chemotherapy., Clin Cancer Res, 11, 5678, 10.1158/1078-0432.CCR-04-2421

LA Carey, 2007, The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes., Clin Cancer Res, 13, 2329, 10.1158/1078-0432.CCR-06-1109

C Liedtke, 2008, Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer., J Clin Oncol, 26, 1275, 10.1200/JCO.2007.14.4147

GC Wishart, 2010, PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer., Breast Cancer Res, 12, R1, 10.1186/bcr2464